 - Participant has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered i.e., Grade 1 or at baseline from adverse events due to a previously administered agent. Prior radiotherapy to the liver is not allowed. Notes: Participants with Grade 2 neuropathy are an exception to this criterion and may qualify for the study. If participant received major surgery, they must have recovered adequately from the toxicity andor complications from the intervention prior to starting therapy. 